Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma

Decreased expression of the transmembrane 4 superfamily member, CD9, is associated with poor prognosis in patients with breast or non-small cell lung cancer. The expression of CD9 in lymphoma was examined in this study. Fifty-one sections with diffuse lymphomas were examined. Thirty-seven had low ex...

Full description

Saved in:
Bibliographic Details
Published inOncology reports Vol. 5; no. 6; p. 1507
Main Authors Yau, J C, Dabbagh, L K, Formenti, K S, Coupland, R W, Burns, B F, Shaw, A R
Format Journal Article
LanguageEnglish
Published Greece 01.11.1998
Subjects
Actuarial Analysis
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, CD - analysis
Antigens, CD - genetics
Biopsy
Disease-Free Survival
Female
Hodgkin Disease - immunology
Hodgkin Disease - pathology
Humans
Immunohistochemistry
Lymphoma, Non-Hodgkin - immunology
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Male
Membrane Glycoproteins
Middle Aged
Neoplasm Staging
Prognosis
Survival Rate
Tetraspanin 29
Online AccessGet more information

Cover

More Information
Summary:Decreased expression of the transmembrane 4 superfamily member, CD9, is associated with poor prognosis in patients with breast or non-small cell lung cancer. The expression of CD9 in lymphoma was examined in this study. Fifty-one sections with diffuse lymphomas were examined. Thirty-seven had low expression and 14 high expression of CD9. At 5 years the progression-free survival rates were 83.3+/-10.8% and 32.8+/-9.2% (p=0.018), and the actual survival were 83.3+/-10.8% and 56.8+/-8.9% (p=0.256) for those with high and low CD9 expression respectively. Decreased expression of CD9 appears to be a prognostic factor for poor survival in patients with diffuse lymphomas.
ISSN:1021-335X
DOI:10.3892/or.5.6.1507